PET Scanning in Parkinson s Disease

Completed

Conditions studied: Schizophrenia, Parkinson's Disease

In brief

This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Daniel Eisenberg, M.D. Using PET with 6-\[F-18\] Fluoro-L-dopa (FDOPA) and (15)0-H2O in a single scan session, both presynaptic dopaminergic function and regional cerebral blood flow (rCBF) are assessed. The kinetic rate constant (Ki) for presynaptic dopaminergic uptake in striatum and other regions is calculated. We compare Ki across subject groups and relate the findings to rCBF. Findings are also related to allelic variation in genes of interest, for determination of which participants sign separate consent for NIH approved protocol 95-M-0150 Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings, PI: Karen F. Berman, MD. We also draw comparisons between subjects with inherited vs. sporadic Parkinson s disease to determine whether the PET phenotype is the same in both groups, and we compare system-level, circuit-based pathophysiology across PD and schizophrenia groups. Each subject is further screened with an MRI to rule out structural abnormalities and also to further delineate areas of interest in the PET scans.

Key facts

Study ID

NCT00024622

Run by

National Institute of Mental Health (NIMH)

People needed

502

Starts

2002-03-15

Last updated by the study team

2026-06-08

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• Will include medical illness that would affect cerebral blood flow or dopamine
• Current pregnancy
• Current breast feeding
• Possible exposure to radiation exceeding RSC guidelines
• History of any (excepting nicotinerelated) DSM5-defined moderate to severe substance use disorder (or DSM-IV-defined substance dependence).
• Cumulative lifetime history of any (excepting nicotine-related) DSM5-defined mild substance use disorder (or any DSM-IV-defined substance abuse),either in excess of 5 years total or not in remission for at least 6 months,
• Inability to stay caffeine- and nicotine-free for 4 hours
• Current suicidality or assaultiveness
• History of movement disorder
• History of head injury requiring hospitalization
• History of coma
• Inability to meet general safety criteria for MRI study (as determined by standardized Nuclear Medicine Research (NMR) Center screening)
• Previously demonstrated inability or unwillingness to comply with a study protocol.
• PARKINSONS DISEASE:
• Individuals not capable of understanding the consent will be excluded.
• HEALTHY VOLUNTEERS:
• Healthy volunteers will be unable to participate if they have been treated with psychotropic medication within the three months prior to scanning, are undergoing current psychiatric treatment, have any history of major psychiatric or movement disorder, have a first degree relative with schizophrenia, or have a family history of PD.

Where it is running

• National Institutes of Health Clinical Center — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.